Amerikanische Gesellschaft für Hirudotherapie

Proton bridging in the interactions of thrombin with hirudin and its mimics

Biochemistry article published in Biochemistry (2013)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSpeichel-PharmakologieArzneimittelentwicklungKovach IM, Kakalis L, Jordan F, Zhang D · Biochemistry, 2013

Abstract

Thrombin is the pivotal serine protease enzyme in the blood cascade system and thus a target of drug design for control of its activity. The most efficient nonphysiologic inhibitor of thrombin is hirudin, a naturally occurring small protein. Hirudin and its synthetic mimics employ a range of hydrogen bonding, salt bridging, and hydrophobic interactions with thrombin to achieve tight binding with K(i) values in the nano- to femtomolar range. The one-dimensional (1)H nuclear magnetic resonance spectrum recorded at 600 MHz reveals a resonance 15.33 ppm downfield from silanes in complexes between human α-thrombin and r-hirudin in pH 5.6-8.8 buffers and between 5 and 35 °C. There is also a resonance between 15.17 and 15.54 ppm seen in complexes of human α-thrombin with hirunorm IV, hirunorm V, an Nα(Me)Arg peptide, RGD-hirudin, and Nα-2-naphthylsulfonyl-glycyl-DL-4-amidinophenylalanyl-piperidide acetate salt (NAPAP), while there is no such low-field resonance observed in a complex of porcine trypsin and NAPAP. The chemical shifts suggest that these resonances represent H-bonded environments. H-Donor-acceptor distances in the corresponding H-bonds are estimated to be <2.7 Å. Addition of Phe-Pro-Arg-chloromethylketone (PPACK) to a complex of human α-thrombin with r-hirudin results in an additional signal at 18.03 ppm, which is 0.10 ppm upfield from the observed signal [Kovach, I. M., et al. (2009) Biochemistry 48, 7296-7304] for thrombin covalently modified with PPACK. In contrast, the peak at 15.33 ppm remains unchanged. The fractionation factors for the thrombin-hirudin complexes are near 1.0 within 20% error. The most likely site of the short H-bond in complexes of thrombin with the hirudin family of inhibitors is in the hydrophobic patch of the C-terminus of hirudin where Glu(57') and Glu(58') are embedded and interact with Arg(75) and Arg(77) and their solvate water (on thrombin). Glu(57') and Glu(58') present in the hirudin family of inhibitors make up a key binding epitope of fibrinogen, thrombin's prime substrate, which lends substantial interest to the short hydrogen bond as a binding element at the fibrinogen recognition site.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., Extramural
Indexed MeSH termsAmino Acid SequenceAntithrombinsBinding SitesHirudinsHumansHydrogen BondingModels, MolecularMolecular Sequence DataNuclear Magnetic Resonance, BiomolecularProtonsThrombin

Zusammenfassung

1H NMR studies at 600 MHz reveal a short hydrogen-bond network at the C-terminal hirudin-thrombin interface (Glu57', Glu58' to Arg75, Arg77), providing structural insight into hirudin's extremely high affinity for thrombin.

Warum dies für die Hirudotherapie relevant ist

This study used 600 MHz nuclear magnetic resonance spectroscopy to investigate short, low-field hydrogen bonds in complexes between human α-thrombin and recombinant hirudin, along with several hirudin mimics (hirunorm IV, hirunorm V, RGD-hirudin) and synthetic thrombin inhibitors such as NAPAP. The findings matter because they identify a proton-bridged binding element involving hirudin's C-terminal Glu(57') and Glu(58') residues interacting with Arg(75) and Arg(77) on thrombin at the fibrinogen recognition site, offering mechanistic insight into the exceptionally tight (nano- to femtomolar K(i)) thrombin inhibition achieved by hirudin and its mimics. The connection to hirudotherapy is only indirect: the abstract does not reference leeches, leech saliva, or therapeutic use, characterizing hirudin solely as a naturally occurring small protein and thrombin inhibitor. The study is limited to spectroscopic and molecular modeling analysis of purified enzyme-inhibitor complexes in vitro, with no in vivo, clinical, or whole-organism data presented.

Zitation

Proton bridging in the interactions of thrombin with hirudin and its mimics.

Kovach IM, Kakalis L, Jordan F, Zhang D · Biochemistry, 2013

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.